Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M41,708Revenue $M2,105Net Margin (%)12.7Z-Score23.4
Enterprise Value $M41,230EPS $3.8Operating Margin %30.6F-Score4
P/E(ttm))135Cash Flow Per Share $-2.0Pre-tax Margin (%)28.6Higher ROA y-yN
Price/Book16.710-y EBITDA Growth Rate %0Quick Ratio5.1Cash flow > EarningsY
Price/Sales17.55-y EBITDA Growth Rate %0Current Ratio5.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %22.0ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)15.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M102ROI % (ttm)53.3Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 416.666%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 416.6624%Add 60.05%1,410
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 416.6624%New holding, 583 sh.583
REGNAndreas Halvorsen 2014-09-30 Reduce-2.35%$296.41 - $364.41
($335.27)
$ 416.6624%Reduce -63.53%1,080,682
REGNRay Dalio 2014-09-30 Reduce-0.04%$296.41 - $364.41
($335.27)
$ 416.6624%Reduce -91.3%1,600
REGNAndreas Halvorsen 2014-06-30 Add2.39%$277.29 - $313.74
($296.6)
$ 416.6640%Add 181.75%2,963,456
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 416.6640%Add 60.34%2,795,500
REGNFrank Sands 2014-06-30 Add0.64%$277.29 - $313.74
($296.6)
$ 416.6640%Add 22.32%4,907,362
REGNRay Dalio 2014-06-30 Buy 0.04%$277.29 - $313.74
($296.6)
$ 416.6640%New holding, 18400 sh.18,400
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 416.6640%New holding, 2295 sh.2,295
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 416.6640%New holding, 881 sh.881
REGNAndreas Halvorsen 2014-03-31 Buy 1.3%$267.62 - $347.62
($307.2)
$ 416.6636%New holding, 1051800 sh.1,051,800
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 416.6636%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 416.6636%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 416.6636%New holding, 6084 sh.6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 416.6645%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 416.6659%Add 20.34%3,777,357
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 416.6659%New holding, 3285 sh.3,285
REGNRay Dalio 2013-09-30 Sold Out -0.01%$227.65 - $309.174
($262.76)
$ 416.6659%Sold Out0
REGNFrank Sands 2013-06-30 Add1.07%$178.51 - $282.8
($232.86)
$ 416.6679%Add 81.03%3,138,793
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
REGN Ken Fisher 2014-12-3152400-10.12%
REGN Ken Fisher 2014-09-3058300New Buy
REGN Joel Greenblatt 2014-09-301,41000.01+60.05%
REGN Frank Sands 2014-09-304,967,4664.894.4+1.22%
REGN Ron Baron 2014-09-307,1090.010.01
REGN Vanguard Health Care Fund 2014-09-302,795,5002.752.6
REGN Mario Gabelli 2014-09-302,19000-4.58%
REGN Andreas Halvorsen 2014-09-301,080,6821.061.6-63.53%
REGN Ray Dalio 2014-09-301,60000-91.3%
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCHLEIFER LEONARD SPresident & CEO 2015-01-02Sell1,500$410.580.99view
Powchik PeterSVP Clinical Development & Reg 2015-01-02Sell10,822$414.080.14view
Sanofi10% Owner 2014-12-24Buy201,459$393.215.45view
McCorkle Douglas SVP Controller and Asst Treasur 2014-12-16Sell8,486$410.151.09view
POON CHRISTINE ADirector 2014-11-25Buy400$4101.13view
GILMAN ALFRED GDirector 2014-11-24Sell40,000$408.441.52view
STAHL NEILSVP Research and Development S 2014-11-24Sell5,307$412.930.41view
Terifay Robert JSVP Commercial 2014-11-18Sell22,362$405.792.18view
Van Plew Daniel PSVP & General Mgr Industrial O 2014-11-13Sell8,575$399.343.83view
SCHLEIFER LEONARD SPresident & CEO 2014-11-12Sell45,817$400.33.58view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 
    Weekly Top Insider Sells: REGN May 27 2013 
    comment on REGN Mar 06 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 


    More From Other Websites
    Drugmakers get mysterious invites to White House Jan 28 2015
    Regeneron, Vertex execs heads to White House Jan 28 2015
    Regeneron/Sanofi's PCSK9 Drug Gets FDA Priority Review - Analyst Blog Jan 27 2015
    Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Jan 27 2015
    Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Jan 27 2015
    2:23 am Regeneron Pharms and Sanofi (SNY) announce Praluent... Jan 27 2015
    Regeneron vaults ahead of Amgen in race to market cholesterol drug Jan 26 2015
    Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race Jan 26 2015
    Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been... Jan 26 2015
    Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been... Jan 26 2015
    Regeneron/Sanofi cholesterol drug gets FDA priority review Jan 26 2015
    Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race Jan 26 2015
    EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due... Jan 23 2015
    EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due... Jan 23 2015
    Ebola vaccine trials to begin in Liberia Jan 22 2015
    US investors double down on biotech bets Jan 22 2015
    Cramer's Stop Trading: Biotech hangover Jan 20 2015
    Regeneron CEO: Choice, not price best for patients Jan 20 2015
    New York drug developer's big money maker had nearly $1.74B in sales last year Jan 14 2015
    REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 13 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK